Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award
Philadelphia, PA – Chimeron Bio, a next generation RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its…
Recent News & Events
Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors
Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™…
Chimeron Bio Welcomes Kevin Heyeck as New CEO
Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™…
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates
Philadelphia, PA and College Station, TX – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed…
Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine
Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESARTM…
Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis
Philadelphia, PA – Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan…